12 research outputs found

    Die Bibliothek als Erfolgsfaktor:

    Get PDF
    Im Jahr 2012 konnte die Universitätsbibliothek ihr 50. Jubiläum feiern. Aus diesem Anlass hat die Bibliothek eine Festschrift herausgegeben. Es findet keine Rückschau auf die Vergangenheit statt. Hingegen wird in drei Themenbereichen "Die Universitätsbibliothek - professionelle Partnerin für Lehre , Studium und Forschung", "Innovationen für die campusweiten Dienstleistungen der Universitätsbibliothek" und "Ein scharfes Profil für die Ruhr-Universität Bochum - der Beitrag der Universitätsbibliothek" auf die Rolle und Funktion der Universitätsbibliothek Bochum bis hin zu aktuellen Veränderungen bei Arbeitsabläufen in der Universitätsbibliothek im Jahr 2012 eingegangen

    Der Mediensport Olympia - ein globales Integrationsritual?

    Full text link
    Die Olympischen Spiele wirken als ein Integrationsritus in einer sich globalisierenden Welt. Der Sport überwindet die Länder-, Kultur- und Rassengrenzen und vereint die Öffentlichkeit mithilfe der Medien. Diese inszenieren die Sportarten gemäß ihrer Wirkungslogik, und verändern somit den Sport selbst. Trotz Skandalen nimmt die Bedeutung der Spiele stetig zu, sie erreichen mit der Eröffnungsfeier das weltweit größte (Fernseh-)Publikum. Diese Feier ist ein globaler sakraler Ritus. Besonders das Fernsehen lässt alle um Ritus teilhaben. Der Sport als soziales Handeln vermittelt einen Glauben an Fortschritt durch Leistung, und die Zuschauer können mithilfe der Medien auch teilnehmen. In Zeiten des Wandels wird der Ritus wichtig für die Gemeinschaft.The Olympic Games appear to be a rite of integration in a world of increasing globalization. Sport overcomes national, cultural und racial boundaries, und unites the public with the help of the media. The media (re)produce the different sports according to the functional logic of their medial presentation und therefore change the sports itself: Economy has replaced morality as the highest precept. Despite certain scandals, the Games become more und more significant. The opening ceremony reaches the largest (TV-)audience worldwide. This ceremony is a global religious rite which could have never been accomplished without the media. It is especially television that enables everyone to be a part of the rite. Sport as social action educates a belief in Progress through achievement, and the audience can participate with the help of the media. In times of constant changes, this rite becomes highly important to the community

    Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas

    Get PDF
    The antibody-drug conjugate polatuzumab vedotin (pola) has recently been approved in combination with bendamustine and rituximab (pola-BR) for patients with refractory or relapsed (r/r) large B-cell lymphoma (LBCL). To investigate the efficacy of pola-BR in a real-world setting, we retrospectively analyzed 105 patients with LBCL who were treated in 26 German centers under the national compassionate use program. Fifty-four patients received pola as a salvage treatment and 51 patients were treated with pola with the intention to bridge to chimeric antigen receptor (CAR) T-cell therapy (n = 41) or allogeneic hematopoietic cell transplantation (n = 10). Notably, patients in the salvage and bridging cohort had received a median of 3 prior treatment lines. In the salvage cohort, the best overall response rate was 48.1%. The 6-month progression-free survival and overall survival (OS) was 27.7% and 49.6%, respectively. In the bridging cohort, 51.2% of patients could be successfully bridged with pola to the intended CAR T-cell therapy. The combination of pola bridging and successful CAR T-cell therapy resulted in a 6-month OS of 77.9% calculated from pola initiation. Pola vedotin-rituximab without a chemotherapy backbone demonstrated encouraging overall response rates up to 40%, highlighting both an appropriate alternative for patients unsuitable for chemotherapy and a new treatment option for bridging before leukapheresis in patients intended for CAR T-cell therapy. Furthermore, 7 of 12 patients with previous failure of CAR T-cell therapy responded to a pola-containing regimen. These findings suggest that pola may serve as effective salvage and bridging treatment of r/r LBCL patients

    Precision Measurement of the Helium Flux in Primary Cosmic Rays of Rigidities 1.9 GV to 3 TV with the Alpha Magnetic Spectrometer on the International Space Station

    Get PDF
    Knowledge of the precise rigidity dependence of the helium flux is important in understanding the origin, acceleration, and propagation of cosmic rays. A precise measurement of the helium flux in primary cosmic rays with rigidity (momentum/charge) from 1.9 GV to 3 TV based on 50 million events is presented and compared to the proton flux. The detailed variation with rigidity of the helium flux spectral index is presented for the first time. The spectral index progressively hardens at rigidities larger than 100 GV. The rigidity dependence of the helium flux spectral index is similar to that of the proton spectral index though the magnitudes are different. Remarkably, the spectral index of the proton to helium flux ratio increases with rigidity up to 45 GV and then becomes constant; the flux ratio above 45 GV is well described by a single power law

    The Internalization Theory of Emotions: A Cultural Historical Approach to the Development of Emotions

    No full text

    Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

    Get PDF
    International audienceState-of-the art therapy for recurrent ovarian cancer suitable for platinum-based re-treatment includes bevacizumab-containing combinations (eg, bevacizumab combined with carboplatin-paclitaxel or carboplatin-gemcitabine) or the most active non-bevacizumab regimen: carboplatin-pegylated liposomal doxorubicin. The aim of this head-to-head trial was to compare a standard bevacizumab-containing regimen versus carboplatin-pegylated liposomal doxorubicin combined with bevacizumab
    corecore